Generic name |
evolocumab |
Strength |
140 mg/mL, 120 mg/mL |
Form |
solution for subcutaneous injection in 1 mL prefilled autoinjector of 140 mg/mL, or 3.5 mL automated mini-doser with prefilled cartridge of 120 mg/mL |
Special Authority criteria |
Approval period |
INITIAL: For the treatment of heterozygous familial hypercholesterolemia (HeFH)1 as an adjunct to maximally tolerated HMG-CoA reductase inhibitors (statins) therapy in adult patients who are unable to reach target low density lipoprotein cholesterol (LDL-C) levels2, when:
OR The patient is unable to tolerate at least 2 HMG-CoA reductase inhibitors (statins)3 OR The patient has confirmed rhabdomyolysis OR Treatment with HMG-CoA reductase inhibitors (statins) is contraindicated AND
|
12 weeks |
RENEWAL: Approval will be granted if the following criteria are met:
AND
AND
|
1 year4,5 |